Epidemiological Characteristics Of Gastric And Pancreatic Cancers In Latin America

Study Overview

Epidemiological Characteristics of Gastric and Pancreatic Cancers in Latin America

Currently, there is no Brazilian or Latin American epidemiological data, such as clinical-pathological characteristics, standard treatments and outcomes of gastric cancer and pancreatic cancer in the region. The study aims to create a Latin American multicenter database to analyze epidemiological, clinical, and pathological data, treatments, outcomes, and biological information from patients with gastric and pancreatic cancer.

Patients diagnosed with gastric and gastroesophageal junction or pancreatic cancer after January 2019 at participating sites will be included. Data will be collected from medical records in selected centers that comprise different countries from Latin America. Data collection will begin on the time of site activation. Patients recruited for this study will be identified in the participating sites. Data from clinical, demographic, and socioeconomic variables will be collected. Also, data on treatments performed and outcomes will be abstracted. The patient data sources will be the medical records of the patients. Patients will continue to receive treatment and clinical evaluations for gastric and gastroesophageal junction or pancreatic cancer according to what is determined by their medical team, according to the usual standards of treatment and clinical practice of each center.

Gastric Cancer
GastroEsophageal Cancer
Pancreatic Cancer

OTHER: Observational study

LACOG0222

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2023-03-08	Results First Submitted N/A	Last Update Submitted that met QC Criteria 2025-02-11
First Submitted that Met QC Criteria 2023-06-20	Results First Submitted that Met QC Criteria N/A	Last Update Posted (ACTUAL) 2025-02-12
First Posted (ACTUAL) 2023-06-29	Results First Posted N/A	Last Verified 2025-02

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
N/A

Allocation:
N/A

Interventional Model:
N/A

Masking:
N/A

Arms and Interventions

Participant Group/Arm	Intervention/Treatment
: Cohort A 120 patients with histological diagnosis of gastric and gastroesophageal junction cancer.	OTHER: Observational study This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
: Cohort B 80 patients histological diagnosis of pancreatic cancer.	OTHER: Observational study This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.

Participant Group/Arm

Intervention/Treatment

: Cohort A

120 patients with histological diagnosis of gastric and gastroesophageal junction cancer.

OTHER: Observational study

This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.

: Cohort B

80 patients histological diagnosis of pancreatic cancer.

OTHER: Observational study

This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.

Primary Outcome Measures	Measure Description	Time Frame
Describe the treatment patterns	Describe the treatment patterns and outcomes of patients with gastric and gastroesophageal junction cancer in Latin America.	During study duration (one year)

Secondary Outcome Measures	Measure Description	Time Frame

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

≥18 years
Histological diagnosis of gastric and gastroesophageal junction cancer (Cohort A) or histological diagnosis of pancreatic cancer (Cohort B);
Advanced disease diagnosis from January 2019: patients can be included prospectively. Advanced disease is defined as metastatic disease or locally advanced disease not amenable to curative therapy;
Availability of adequate medical data for data collection.

Synchronous invasive tumor or second primary tumor in the last three years (except thyroid tumors or non-melanoma skin);
Nonepithelial histology in Cohort A: Sarcoma, GIST, lymphoma, and tumors of neuroendocrine origin;
Nonepithelial histology in Cohort B: Sarcoma, GIST, lymphoma, pancreatoblastoma, and tumors of neuroendocrine origin.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Astellas Pharma Inc
Grupo Argentino de Investigación Clínica en Oncología (GAICO)

Investigators

PRINCIPAL_INVESTIGATOR: Renata D´Alpino Peixoto, Latin American Cooperative Oncology Group

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Learn

Resources

PatientS

Caregivers

Clinical Trial Record